Ropes & Gray represented AvenCell Therapeutics in the transaction, and Wilson Sonsini Goodrich & Rosati advised Novo Holdings and F-Prime Capital on the transaction. AvenCell Therapeutics...
AvenCell Therapeutics’ $112 Million Series B Funding Round
Verona Pharma’s US FDA Approval of Ohtuvayre™
Wilson Sonsini Goodrich & Rosati advised Verona Pharma on patent matters on the deal. Verona Pharma plc (Nasdaq: VRNA) announced that the U.S. Food and Drug...
Constructive Bio’s $58 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati advised Ahren, OMX Ventures, +ND Capital, and Fine Structures Ventures on the transaction. Constructive Bio, a pioneering synthetic genomics company, announced...
FluoRok’s £7.7 Million Oversubscribed Funding Round
Wilson Sonsini Goodrich & Rosati advised FluoRok on patent matters related to the transaction. FluoRok, a deep-tech start-up focused on fluorochemical manufacturing, announced the completion of...
ONL Therapeutics’ $65 Million Series D Financing Round
Taft Stettinius & Hollister advised ONL Therapeutics on the transaction, and Wilson Sonsini Goodrich & Rosati advised the company on patent matters. ONL Therapeutics, Inc. announced...
eGenesis’ $191 Million Series D Financing Round
Wilson Sonsini Goodrich & Rosati advised eGenesis on the transaction. eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, announced the...
Ochre Bio’s $37.5 Million License Agreement with GSK
Wilson Sonsini Goodrich & Rosati represented Ochre Bio in the transaction. Ochre Bio, a pioneer in chronic liver disease medicine development, announced the start of a...
Amber Therapeutics’ $100 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati advised Amber on the transaction. Amber Therapeutics, a UK-based medical technology company, announced it closed a Series A financing, raising $100...
Stoke Therapeutics’ $125 Million Upsized Common Stock Offering
Fenwick & West advised Stoke Therapeutics on the offering, Wilson Sonsini Goodrich & Rosati advised Stoke on IP matters and Davis Polk & Wardwell advised the...
Prime Medicine’s $161.0 Million Common Stock Offering
Goodwin Procter advised Prime Medicine and Wilson Sonsini Goodrich & Rosati advised Prime Medicine on IP matters related to the transaction, while Davis Polk & Wardwell...
Arena BioWorks’ Launch
Wilson Sonsini Goodrich & Rosati advised Arena BioWorks on patent and transactional matters. Arena BioWorks announced its launch as a biomedical research institute with a mission...
CARGO Therapeutics’ $281.3 Million Initial Public Offering
Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised CARGO Therapeutics, Inc. on the offering, and Cooley advised the underwriters. CARGO Therapeutics, Inc. (CARGO) (Nasdaq:CRGX)...